drugset / Trial / NCT05407142
An Open Comprative Study of the Prophylactic Efficacy and a Non-comparative Study of the Immunogenicity and Safety of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine (CoviVac)
Phase 3
Unknown
29000 enrolled
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products
Non-randomizedParallel-groupSingle-blindPrevention
Summary
An Open Comprative Study of the Prophylactic Efficacy and a Non-comparative Study of the Immunogenicity and Safety of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine (CoviVac), Produced by FSBSI "Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products", on Volunteers at the Age of 18-60 Years
Timeline
- Start
- 2021-07-07
- Primary completion
- 2023-06-01
- Completion
- 2023-12-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CoviVac | Vaccine | 0.5 ml | Intramuscular |